Abcam has established a complete industrial chain covering antibody research and development, production, validation, and sales, with over 110000 types of antibody and reagent products. The company has innovatively launched the "Abcam Antibody Validation Program" to ensure the specificity and reliability of antibodies through various experimental methods. Abcam has also developed an advanced digital platform that provides detailed product data and technical support. The company maintains close cooperation with top global research institutions and biopharmaceutical companies, and its products are sold to more than 130 countries and regions, continuously promoting the progress of life science research.

In 2023, Abcam was acquired by Danaher for approximately $5.7 billion, becoming an important component of its life sciences business unit. After privatization, Abcam accelerates the integration of automated production and AI technology to improve product development efficiency. The company has recently focused on multi omics research and precision medicine, launching new reagent products such as single-cell analysis and spatial biology. In the future, Abcam will continue to expand its global market coverage, deepen cooperation with pharmaceutical companies, and consolidate its leading position in the field of scientific research reagents.